Copyright
©The Author(s) 2020.
World J Clin Oncol. Dec 24, 2020; 11(12): 983-989
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.983
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.983
Trial | Ref. | Design | Population | Number of lesions | Local treatment | PFS | OS |
SABR-COMET | Palma et al[11] | Phase II, n = 99 | ≤ 5 locations; different tumour types (lung cancer; n = 18) | 1-5 | SABR | 12 mo vs 6 mo, (P = 0.0012) | 41 mo vs 28 mo, (P = 0.09) |
Iyengar et al[12] | Phase II, n = 29 | Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT) | 1-5 | SABR | 9.7 mo vs 3.5 mo, (P = 0.01) | Not reported | |
“Oligomez” | Gomez et al[13] | Phase II, n = 49 | Lung cancer patients treated with induction chemotherapy followed by standard maintenance treatment (+/-SBRT) | 1-3 | XRT or Surgery | 14.2 mo vs 4.4 mo, (P = 0.022) | 41.2 mo vs 17 mo, (P = 0.017) |
SINDAS | Wang e et al[14] | Phase III, n = 133 | Front line treatment for EGFR + NSCLC patients with ≤ 5 metastases. EGFR-TKI vs SBRT + EGFR-TKI | 1-5 | SBRT | 20.2 mo vs 12.5 mo, (P < 0.01) | 25.5 mo vs 17.4 mo, (P < 0.01) |
- Citation: Mielgo-Rubio X, Garde-Noguera J, Juan O, Couñago F. Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. World J Clin Oncol 2020; 11(12): 983-989
- URL: https://www.wjgnet.com/2218-4333/full/v11/i12/983.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i12.983